Trade Summary Ticker: NGM (Last: $13.01) Entry: $12.70-13.0 Price Target: $14.50-20.00 Target Time-frame: 1-8 weeks Source: Trading View Trade Thesis NGM recovered as I … [Read more...] about NG-mother-effin-M
NASH
A High-Risk, High-Reward Biotech Stock Targeting NASH Cirrhosis
In this next article in our series on investing in NASH I want to jump to the other end of the spectrum. In "Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years" I painted a … [Read more...] about A High-Risk, High-Reward Biotech Stock Targeting NASH Cirrhosis
An Attractive Biotech Stock Gunning For NASH
In my previous article "Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years" I laid out my rationale for investing in NAFLD/NASH companies. I reasoned that by investing in … [Read more...] about An Attractive Biotech Stock Gunning For NASH
Investor Alert: Endra Life Scienes (NDRA)
Background Endra Life Sciences (NDRA) is a clinical stage medical device company we started following in April, 2019. The share price galloped up to a high near $3.30 in March in anticipation of … [Read more...] about Investor Alert: Endra Life Scienes (NDRA)
Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years
Some of the hottest stocks on the market are in the biotech sector. Of these, some of the hottest of the hot are in the NAFLD/NASH space. The reason being is the magnitude of disease prevalence and … [Read more...] about Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years
Technically Swinging CNAT
Swing Thesis This swing-trade for Conatus Pharmaceuticals, (Nasdaq: CNAT) is based on Technical Analysis (which aligns with some key dates) and a fundamental component. With regards to technical … [Read more...] about Technically Swinging CNAT
GALT Director Sells 30K Shares
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. A form-4 just filed on 02/04/2019 by Galectin Therapeutics (Nasdaq: GALT) reports that GALT director … [Read more...] about GALT Director Sells 30K Shares
GALT Announces Extension of Retention Bonuses
Leave a comment and click here to sub for MS article alerts and our newsletter! On January 16th, 2019 Galectin Therapeutics (Nasdaq: GALT) board of directors approved the extension of … [Read more...] about GALT Announces Extension of Retention Bonuses
Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX
leave a comment and click here to sub for MS article alerts and our newsletter Introduction MS noticed some insightful parallels between when Conatus Pharmaceuticals (Nasdaq: CNAT) … [Read more...] about Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX
Post-ENCORE-PH Interview With CNAT
Leave a comment and click here to sub for MS article alerts and our newsletter On the heels of the contentious revealing of ENCORE-PH top-line data MS Money Moves decided to go to the source for … [Read more...] about Post-ENCORE-PH Interview With CNAT
You must be logged in to post a comment.